LEADER 05332nam 22006854a 450 001 9910144095703321 005 20170815120404.0 010 $a1-281-93869-6 010 $a9786611938697 010 $a0-470-40977-0 010 $a0-470-40976-2 035 $a(CKB)1000000000553966 035 $a(EBL)380505 035 $a(OCoLC)299032883 035 $a(SSID)ssj0000161766 035 $a(PQKBManifestationID)11155993 035 $a(PQKBTitleCode)TC0000161766 035 $a(PQKBWorkID)10199097 035 $a(PQKB)10729631 035 $a(MiAaPQ)EBC380505 035 $a(PPN)243322968 035 $a(EXLCZ)991000000000553966 100 $a20080509d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGenomics in drug discovery and development$b[electronic resource] /$fDimitri Semizarov, Eric Blomme 210 $aHoboken, N.J. $cWiley$dc2009 215 $a1 online resource (496 p.) 300 $aDescription based upon print version of record. 311 $a0-470-09604-7 320 $aIncludes bibliographical references and index. 327 $aGenomics in Drug Discovery and Development; Contents; Preface; ACKNOWLEDGMENTS; 1. Introduction: Genomics and Personalized Medicine; 1.1. Fundamentals of Genomics; 1.2. The Concept of Personalized Medicine; 1.3. Genomics Technologies in Drug Discovery; 1.4. Scope of This Book; References; 2. Genomics Technologies as Tools in Drug Discovery; 2.1. Introduction to Genomics Technologies; 2.2. Gene Expression Microarrays: Technology; 2.2.1. Standard Microarray Protocol; 2.2.2. Monitoring the Quality of Input RNA for Microarray Experiments 327 $a2.2.3. Specialized Microarray Protocols for Archived and Small Samples2.2.4. Quality of Microarray Data and Technical Parameters of Microarrays; 2.2.5. Reproducibility of Expression Microarrays and Cross-Platform Comparisons; 2.2.6. Microarray Databases and Annotation of Microarray Data; 2.2.6.1. Target Identification; 2.2.6.2. Disease Classification; 2.2.6.3. Compound Assessment; 2.3. Gene Expression Microarrays: Data Analysis; 2.3.1. Identification of Significant Gene Expression Changes; 2.3.2. Sample Classification and Class Prediction with Expression Microarrays 327 $a2.3.3. Pathway Analysis with Gene Expression Microarrays2.3.4. Common Problems Affecting the Validity of Microarray Studies; 2.4. Comparative Genomic Hybridization: Technology; 2.5. Comparative Genomic Hybridization: Data Analysis; 2.6. Microarray-Based DNA Methylation Profiling; 2.7. Microarray-Based MicroRNA Profiling; 2.8. Technical Issues in Genomics Experiments and Regulatory Submissions of Microarray Data; 2.8.1. Study of a Drug's Mechanism of Action by Gene Expression Profiling; 2.8.2. Early Assessment of Drug Toxicity in Model Systems 327 $a2.8.3. Biomarker Identification in Discovery and Early Development2.8.4. Patient Stratification in Clinical Trials with Gene Expression Signatures; 2.8.5. Genotyping of Patients in Clinical Studies to Predict Drug Response; 2.9. Conclusion; References; 3. Genomic Biomarkers; 3.1. Introduction to Genomic Biomarkers; 3.2. DNA Biomarkers; 3.2.1. DNA Copy Number Alterations; 3.2.1.1. DNA Copy Number Alterations in Cancer; 3.2.1.2. DNA Copy Number Alterations in Other Diseases; 3.2.1.3. Identification of DNA Copy Number Biomarkers in Drug Discovery; 3.2.2. Mutations; 3.2.2.1. p53 Mutations 327 $a3.2.2.2. K-ras Mutations3.2.2.3. EGFR Mutations; 3.2.2.4. Bcr-abl and KIT Mutations; 3.2.3. Epigenetic Markers; 3.3. RNA Biomarkers; 3.3.1. Gene Expression Biomarkers Validated as Diagnostic Tests; 3.3.2. Other Examples of Gene Expression Biomarkers; 3.4. Clinical Validation of Genomic Biomarkers; References; 4. Fundamental Principles of Toxicogenomics; 4.1. Introduction; 4.2. Fundamentals of Toxicogenomics; 4.2.1. Principle of Toxicogenomics; 4.2.2. Technical Reproducibility; 4.2.3. Biological Reproducibility; 4.2.4. Species Extrapolation; 4.3. Analysis of Toxicogenomics Data 327 $a4.3.1. Compound-Induced Gene Expression Changes 330 $aEarly characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists 606 $aPharmacogenomics 606 $aDrug development 606 $aGenetic toxicology 606 $aDNA microarrays 615 0$aPharmacogenomics. 615 0$aDrug development. 615 0$aGenetic toxicology. 615 0$aDNA microarrays. 676 $a615 676 $a615.19 700 $aSemizarov$b Dimitri$0924225 701 $aBlomme$b Eric$0924226 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144095703321 996 $aGenomics in drug discovery and development$92074089 997 $aUNINA